These results suggest that NURR1 not only could directly transactivate the CTNNB1 and increase the protein expression levels of β-catenin but also enhance the nuclear translocation of active β-catenin to mediate the activation of β-catenin signaling in prostate cancer cells. Here, NR4A2 is linked to prostate carcinoma.